-
Product Insights
Tularaemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Symptoms of Tularaemia include skin ulcer, swollen and painful lymph glands, fever, and chills. The Tularaemia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report...
-
Product Insights
Leishmaniasis (Kala-Azar) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leishmaniasis (Kala-Azar) is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms of Kala-Azar include weight loss, low blood counts, enlargement of the liver and spleen, and fever. Treatment includes anti-parasitic drugs. The Leishmaniasis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Leishmaniasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Product Insights
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in...
-
Product Insights
Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections – Drugs In Development, 2022, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor...
-
Product Insights
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus...